Tumor Necrosis Factor-alpha Levels and Cardiac Functions in Type 1 Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

January 30, 2024

Study Completion Date

February 1, 2024

Conditions
Diabetes Mellitus, Type 1Systolic DysfunctionDiastolic Dysfunction
Interventions
DIAGNOSTIC_TEST

transthoracic echocardiography

All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.

Trial Locations (1)

73000

Sirnak State Hospital, Şırnak

All Listed Sponsors
lead

Sirnak State Hospital

OTHER_GOV

NCT06129448 - Tumor Necrosis Factor-alpha Levels and Cardiac Functions in Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter